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Abstract
The  endocannabinoid  system with  cannabinoid  receptors,  specifically  cannabinoid
receptor type 1 (CB1R), and their endogenous activators, the endocannabinoids, has
emerged as an important neuromodulator system. Our understanding of the endocan‐
nabinoid system has significantly advanced in limbic system areas such as the hippo‐
campus and the amygdala. However, the study of this signaling system in the olfactory
pathway is still in its infancy. Here, we review the role of endocannabinoids as signal‐
ing molecules in activity-dependent regulation of dynamically changing neural networks
in the limbic and olfactory system and the relevance of the endocannabinoid system for
synaptic plasticity. We highlight the prospects for cannabinoid-based therapies in the
treatment of various brain disorders and the role of endocannabinoids as neuroprotec‐
tive agents. An increased understanding of cannabinoid signaling has the potential to
pave the way for developing cannabis-related substances as medications.
Keywords: amygdala, hippocampus, olfactory bulb, neuroprotection, retrograde sig‐
naling, neural plasticity
1. Introduction
Over the past decade, the endocannabinoid system with cannabinoid receptors, specifically
cannabinoid receptor type 1 (CB1R), and their endogenous activators, the endocannabinoids,
has been implicated as an important modulatory system in function and dysfunction of many
brain areas. Endocannabinoids are small lipids that regulate normal behaviors, including pain
reception [1] and feeding [2, 3]. Likewise, cannabinoids have therapeutic potential [4]. Endo‐
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cannabinoids show a neuroprotective role against acute excitotoxicity [5] and facilitate functional
recovery after brain injury [6]. They regulate human airway function and provide a means to
treat respiratory pathologies [1]. Cannabinoids are widely used as recreational and psychoac‐
tive drugs and interact with other drugs of abuse, indicating the need to understand the
endocannabinoid system and the neurobiological substrate of its mood-altering capacity [7, 8].
Furthermore, the endocannabinoid system is crucially involved in processes of learning and
memory, for example, in the extinction of aversive memories [9]. Endocannabinoids influence
synaptic transmission and different forms of short- and long-term plasticity [10–12]. They also
influence  growth and development  such as  synapse  formation and neurogenesis.  Other
biological functions and human behaviors modulated by endocannabinoids include eating and
anxiety [2, 3, 13].
A hallmark feature of endocannabinoids is their ability to serve as retrograde signaling
molecules between activated postsynaptic principal neurons and presynaptic interneurons
that express CB1R [10, 12, 14]. While the breadth of endocannabinoid function has become
increasingly clear over the past years, we still have much to learn about their detailed signaling
mechanisms.
Our understanding of the endocannabinoid system has significantly advanced in limbic
system areas such as the hippocampus and the amygdala. However, the study of this signaling
system in the olfactory pathway is still in its infancy. Recent work has started to shed light on
the role of the endocannabinoid system in the olfactory pathway, specifically in the olfactory
bulb as well as for its output to higher order olfactory centers and its centrifugal input [3, 15].
Here, we review the role of endocannabinoids as signaling molecules in activity-dependent
regulation of dynamically changing neural networks in the limbic and olfactory system and
the relevance of the endocannabinoid system for synaptic plasticity. We highlight the prospects
for cannabinoid-based therapies in the treatment of various brain disorders such as epilepsy
[16, 17]. An increased understanding of cannabinoid signaling may pave the way for devel‐
oping cannabis-related substances as antiseizure medications.
2. Endocannabinoids as brain-derived signaling molecules
Endocannabinoids are fatty acid-derived endogenous ligands for Gi/o-protein-coupled CB1Rs
[11]. Endocannabinoids are synthesized from membrane lipids [18]. They can diffuse through
cellular membranes and are thus able to activate receptors in the same manner as exogenously
applied cannabinoids such as the plant-derived compound Δ9-tetrahydrocannabinol, THC, the
bioactive ingredient of the drugs marijuana and hashish. Marijuana (cannabis) is a commonly
abused illicit and recreational drug. The brain produces two endogenous cannabinoids, N-
arachidonoylethanolamide (anandamide (AEA)) and 2-arachidonoylglycerol (2-AG). The two
endocannabinoids bind to CB1R and have the same functional activity as marijuana. Based on
the structural similarity between THC and endocannabinoids, THC is able to activate CB1R
and, thereby, hijack this brain communication system. The evolutionary origin of this com‐
munication system rests with endogenously produced cannabinoids that bind and activate
Cannabinoids in Health and Disease12
CB1R. The discovery of AEA and 2-AG occurred in the 1990s ([19–21], for review see [22]). It
took another decade before the function of these two cannabinoids in brain signaling was
discovered. It is now well known that endocannabinoids serve as retrograde messengers.
Endocannabinoids diminish excitatory and inhibitory transmission. Numerous studies have
established their function as retrograde signals in various brain regions: the hippocampus [23–
28], cerebellum [29–31], neocortex [32, 33], amygdala [34, 35], and olfactory bulb [15]. Further‐
more, in the mediobasal hypothalamus, retrograde endocannabinoid signaling represents a
key mechanism under physiological and pathological conditions whereby gonadotropin-
releasing hormone (GnRH) neurons control their excitatory GABAergic inputs [36, 37].
Endocannabinoid signaling is terminated by reuptake into neurons and glia. AEA is hydro‐
lyzed enzymatically inside the cell by fatty acid amide hydrolase (FAAH), whereas 2-AG is
hydrolyzed by monoacylglycerol lipase (MAGL) [38].
Endocannabinoids serve as important signaling molecules throughout the body including the
nervous system [10, 12, 39–44]. Endocannabinoids play important roles in bodily processes
during both health and disease [45–48]. Their role in bodily functions has been shown for
vertebrates and invertebrates [48]. Pharmacological and physiological experiments in brain
slices have described novel aspects of classic brain signaling mechanisms and/or revealed
unknown mechanisms of cellular communication involving the endocannabinoid system [41,
49–51]. Endocannabinoids are involved in several forms of cellular signaling [49]. The most
distinguishing feature of endocannabinoids is their ability to act as retrograde messengers in
neural circuits as first shown in the hippocampus [10, 26, 52].
3. Distribution of cannabinoid receptors in the CNS
Endocannabinoids, together with their G-protein-coupled cannabinoid receptors, form the
endocannabinoid system. This system also includes an associated biochemical machinery with
endocannabinoid precursors, synthetic and degradative enzymes for these lipidic neurotrans‐
mitters, and transporters [10, 12, 14, 40]. Cannabinoid receptors exist in all normal brains and
serve many essential brain functions when activated by their natural ligands. Two types of
cannabinoid receptors, CB1 (CB1R) and CB2 receptors with 44% amino acid sequence homol‐
ogy, have been described [53, 54]. They are not homogeneously expressed throughout the
body; rather, CB1R is the most abundant G-protein-coupled receptor in the brain [55]. In
contrast, CB2R is found mainly in immune cells and peripheral tissues [54]. More recent
evidence suggests that CB2R is also present in the brainstem, cortex, and cerebellar neurons
and microglia [56, 57]. CB1R has a high level of expression in the brain [58, 59], with a
particularly strong presence at presynaptic axons terminals [60, 61]. THC, the bioactive
ingredient of the drugs marijuana and hashish [62], and other cannabis-derived drugs are
potent activators of CB1R. These drugs artificially activate CB1R and act as exogenous
cannabinoids. CB1R is found in normal brains and carries out critical brain functions [55, 58,
59] principally through a Gi/o-protein-coupled mechanism with CB1R.
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4. Mechanism of endocannabinoid action: retrograde signaling
Endocannabinoids mediate an unconventional type of neuronal communication, called DSI,
depolarization-induced suppression of inhibition (reviewed in [10, 22, 39]). In this communi‐
cation system, a depolarized postsynaptic principal neuron releases endocannabinoids to
regulate neurotransmitter release of presynaptic interneuron. Experimentally, a short rise in
intracellular calcium concentration in a principal neuron, for example, a pyramidal cell of the
hippocampus, results in a transient decline of incoming inhibitory signals in the form of the
neurotransmitter GABA arriving from other neurons. During DSI, endocannabinoids travel
from the postsynaptic neuron to the presynaptic GABA-releasing interneuron and turn off
neurotransmitter release through activation of potassium channels and blockade of calcium
channels. Classical chemical synapses are comprised of a presynaptic, neurotransmitter-
releasing neuron and an activated postsynaptic neuron. For example, synaptic GABA release
from an inhibitory hippocampal interneuron inhibits glutamatergic pyramidal cells. In
contrast, in DSI, the inhibitory input onto an activated pyramidal cell is reduced. In DSI,
endocannabinoids are retrograde signaling molecules. They communicate between postsy‐
naptic pyramidal cells and presynaptic inhibitory interneurons resulting in a reduction of
GABA release. Chemically, endocannabinoids are lipids. Therefore, their ability to diffuse in
the watery extracellular environment of neurons is limited. Subsequently, DSI is a temporary
phenomenon to allow individual neurons to pharmacologically break synaptic connections
from their neighbors and, thereby, encode information [10]. DSI was mimicked by activating
cannabinoid receptors whereas blockade of cannabinoid receptors prevented DSI [24, 26]. A
corresponding phenomenon, DSE, depolarization-induced suppression of excitation, mediat‐
ed by retrograde action of endocannabinoids, was identified at cerebellar excitatory synapses
[28]. DSI and DSE are based on a presynaptic effect as shown by an increase in calcium in the
postsynaptic cells and corresponding changes in paired pulse ratio of neurotransmitter release.
5. Endocannabinoids in the olfactory system
The main olfactory bulb offers an ideal platform for investigating how the endocannabinoid
system modulates a functional neural network to achieve an integrated outcome. On the one
side, the olfactory bulb directly receives sensory input from the nasal epithelium, and on the
other side, it receives strong centrifugal cortical input that even outnumbers the cortical
projections from the olfactory bulb. This structural organization makes the olfactory bulb
preparation significantly different from the hippocampus, amygdala, neocortex, and cerebel‐
lum to address functional questions of CB1R modulation in the brain.
As detailed below, new evidence demonstrates that CB1R-mediated retrograde signaling
exists among olfactory bulb glomerular neurons such that endocannabinoids released from
glomerular neurons function as retrograde messengers to control the excitability of presynap‐
tic neurons and to regulate their transmitter release [15]. Endocannabinoids have a distinct
effect on sensory input, that is, they are involved in gain control through regulating presynaptic
inhibition. Another new work emphasizes the relevance of cortical feedback to the olfactory
bulb as a means to control odor detection and establishes the relationship of food intake and
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olfactory processing [3]. The endocannabinoid system is a key player in these signaling
pathways.
Odorants in the air that we breathe in activate olfactory receptor cells in the nasal epithelium.
Each receptor cell sends an axon to the ipsilateral main olfactory bulb which serves as the first
relay station in the central nervous system for processing olfactory sensory information.
Cannabinoid receptors are expressed at high levels in the olfactory bulb, specifically in the
input region, the glomerular layer [58, 63–65]. Furthermore, neurons in the glomerular layer
are immunoreactive for enzymes that synthesize endocannabinoids [66–68]. Electrophysio‐
logical evidence has now established that the endocannabinoid system plays a functional role
in regulating neuronal activity and signaling in olfactory bulb glomeruli [15].
Three types of neurons are housed in the glomerular layer of the main olfactory bulb, that is,
these neurons have their cell bodies in the glomerular layer: periglomerular (PG), external
tufted (eTC), and short-axon (SA) cells, reviewed in Ref. [49]. PG cells are neurochemically and
functionally heterogeneous [69–71]. They are GABAergic, whereas SA cells express both
GABA and dopamine and eTC cells are glutamatergic [71–73]. PG cells receive input from the
olfactory nerve or dendrodendritic glutamatergic input from eTC or mitral cells, for example,
as spontaneous bursts of excitatory postsynaptic currents (EPSCs) [70, 74, 75]. PG cells
presynaptically inhibit olfactory receptor neurons through GABAergic transmission [76, 77].
eTC cells receive spontaneous bursts of inhibitory postsynaptic currents (sIPSCs) from PG cells
at inhibitory GABAergic synapses as well as spontaneous glutamatergic EPSCs [77, 78].
Endocannabinoids are likely to be released by activated eTC cells in the glomerular layer.
Membrane properties of PG cells are potently regulated by cannabinoid drugs such as the
CB1R antagonist AM251 and the potent CB1R agonist WIN 55,212-2 (WIN) [15, 49]. Cannabi‐
noid receptors directly regulate PG cells since the effects of AM251 and WIN persist in the
presence of ionotropic glutamate and GABAA receptor blockers (synaptic blockers: CNQX,
APV, gabazine) [15], indicating that CB1R is expressed in PG cells. AM251 increases action
potential firing of PG cells and triggers release of GABA. eTC cells are synaptic targets of PG
cells such that CB1R-mediated effects on PG cells are affecting chemical synaptic transmission
to eTC cells. CB1R is also expressed in eTC cells and may participate in modulating eTC cell
activity.
Cannabinoid drugs such as AM251 or WIN have no effect on membrane properties such as
firing frequency or membrane potential in eTC cells [15, 49]. In the presence of synaptic
blockers, cannabinoid drugs have a modest effect on eTC cells such that AM251 slightly
increases the firing rate of eTC cells without membrane depolarization. WIN slightly decreases
firing of eTC cells in synaptic blockers without a clear change in membrane potential. The
effects of AM251 and WIN in the presence of synaptic blockers, that is, during pharmacological
isolation of eTC cells, indicate that CB1R mediates a direct effect on eTC cells. The direct
excitatory effect of AM251 is relatively weak and contrasted by strong GABAergic input from
PG cells onto eTC cells, namely, the enhanced GABA release from PG cells. The strong
inhibitory effect mediated by AM251 acting on PG cells overshadows the direct AM251-evoked
excitation of eTC cells.
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Experimental evidence indicates direct and indirect effects of cannabinoid drugs on glomer‐
ular neurons [15]. In order to determine if endocannabinoids are involved in retrograde
signaling in the glomerular neural circuitry, that is, if DSI is present, eTC cells are activated by
a 5 s depolarizing voltage step from a holding potential of −60 mV to 0 mV. In eTC cells DSI
is visible as a decrease in the amplitude and frequency of sIPSCs. A single depolarizing step
evokes a suppression of sIPSC area by ~40% of control which then gradually recovers.
Projection or output neurons in the main olfactory bulb can show regular action potential firing
or burst firing. eTC cells exhibit a distinct intrinsic bursting pattern [73]. In order to mimic their
spontaneous rhythmic bursting, a train of depolarizing steps can be applied to an eTC cell
which allows determining a possible functional role of DSI in olfactory glomeruli. A train of
depolarizing steps results in a transient 60% reduction in sIPSC area (20 steps, 0.75 Hz). DSI
can be completely eliminated in the presence of AM251, indicating that DSI is mediated by
CB1R. eTC cells burst at a range from 0.5 to 6.5 Hz with a mean frequency of 2.7 bursts/s [73].
Depolarizing voltage pulses at 2 Hz (20 steps, pulse duration: 250 ms) evoke DSI as a reduction
of sIPSCs in eTC cells, similar to the results obtained with voltage steps at 0.75 Hz to 0 mV. In
eTC cells, single depolarizing voltage steps as well as a train of voltage steps evoke suppression
of inhibition (DSI). The evidence suggests that spontaneous rhythmic bursting of eTC cells
triggers the release of endocannabinoids which function as retrograde messengers to reduce
GABA release from PG cells [15, 49]. This, in turn, regulates the activity of PG cell synaptic
targets such as eTC cells.
The results indicate that endocannabinoids regulate neuronal activity and signaling in
olfactory bulb glomeruli and function in DSI through CB1R-mediated retrograde signaling
among glomerular neurons [15, 49]. Endocannabinoids are synthesized and released from
neuronal cell bodies as a result of cellular excitation [11]. Endocannabinoids in the olfactory
bulb are likely to be synthesized and released from neurons that synapse with presynaptic
cells, that is, PG cells, and receive feedback synaptic input from them. eTC cells could be a
potential endocannabinoid source in the olfactory bulb which is supported by the fact that DSI
is found in eTC cells. The extent of DSI in eTC cells is subject to the level of cellular activation,
that is, voltage step duration and step number. DSI cannot be evoked with step durations of
1 s or less, while a step duration closer to 5 s evokes transient DSI. Likewise, increasing the
number of number steps to more than three evokes strong DSI and inhibits sIPSCs. When eTC
cells are activated and show rhythmic burst firing, endocannabinoids are released which in
turn affects glomerular activity. Bursting is an intrinsic property of eTC cells [73, 78] and
regulates the release of endocannabinoids from principal olfactory bulb neurons such as eTC
cells. Bursting-induced endocannabinoid release may also occur also in other brain systems
and represent a general phenomenon of endocannabinoid signaling.
Recently, the endocannabinoid system has been placed in a behavioral context by linking an
internal metabolic state (hunger) to sensory perception and subsequent behavior, namely, food
intake [3]. CB1 receptor-dependent control of excitatory drive from centrifugal feedback
projections to the main olfactory bulb determines the efficiency of olfactory processes and food
intake in fasted mice. This study focuses on neural processes deeper in the olfactory bulb,
primarily involving those olfactory bulb neurons (GABAergic granule cells) that receive heavy
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CNS feedback rather than direct sensory input from the nasal epithelium. Given this structural
organization of the main olfactory bulb, the authors integrate three separate neural compo‐
nents: sensory (olfactory) input, central processing in the main olfactory bulb, and behavioral
output in terms of feeding in the overall framework of the internal state of the animal (hunger).
Cortical feedback to the main olfactory bulb is a means to control odor detection. The rela‐
tionship of food intake and olfactory processing implicates the endocannabinoid system as a
key player in this signaling pathway. Thereby, the endocannabinoid system helps to resolve
the old question of how the smell of a cookie makes us want to eat it and which brain mech‐
anism allows us to find food more rapidly and reliably when we are hungry. CB1 receptor-
dependent control of olfactory processes has a determinant role in coupling the internal state
of hunger with the execution of the behavior such as increased food intake. THC has an effect
on both olfactory detection thresholds and habituation, while the latter effect had no correla‐
tion to food intake. The authors suggest that enhancement of olfactory detection is likely the
main mechanism linking (endo)cannabinoid signaling in the main olfactory bulb to increased
food intake. Possibly, by reducing overall granule cell-mediated inhibition of mitral cells, the
key output neurons of the main olfactory bulb, mitral cells become more sensitive and that
would lower the odor detection threshold. The authors suggest that activation of CB1R on
terminals of feedback cortical centrifugal glutamatergic neurons in the main olfactory bulb
directly reduces the excitatory drive onto granule cells, thereby regulating mitral cell activity
to increase odor detection and food intake [3]. However, other cellular mechanisms might
come into play as well. These mechanisms could work in the peripheral input region of the
main olfactory bulb rather than in the deeper granule cell layer. Also, glutamatergic input to
the main olfactory bulb is not the only centrifugal input. Rather, other areas of the brain also
provide feedback cortical projections with cholinergic, dopaminergic, serotonergic, or
noradrenergic input [69, 79] and might be subject to CB1R modulation.
6. Cannabinoid receptors and hippocampal neural plasticity
Our understanding of the endocannabinoid system has greatly benefited from studies of limbic
system areas such as the hippocampus. Work in hippocampal slices first established the role
of endocannabinoids as retrograde signaling molecules [26, 80]. One of the main functions of
the hippocampus is to convert short-term memory into long-term memory [81]. A hippocam‐
pal formation exists in both hemispheres of the brain and is made up of the hippocampus, the
dentate gyrus, and the parahippocampal gyrus. The hippocampus is composed of four regions
called cornu ammonis, or CA1, CA2, CA3, and CA4. The parahippocampal gyrus contains the
entorhinal cortex and the subiculum. The entorhinal cortex is connected to parts of the cerebral
cortex; and the thalamus, the hypothalamus, and the brain stem send axons into the entorhinal
cortex [82]. The organization of the hippocampal formation lends itself to the flow of infor‐
mation. Information flows along the perforant pathway in the hippocampus. Pyramidal cells,
originating in the entorhinal cortex, extend axons into the granule cells of the dentate gyrus
with secondary outputs into the CA1 and CA3 regions. They extend from the dentate gyrus
into the CA3 region through granule cell axons (mossy fiber pathway). CA3 pyramidal cell
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axons extend into the CA1 region and connect to fibers from the contralateral hippocampus.
CA1 pyramidal cells project back into the entorhinal cortex and into the subiculum. The
afferent fibers then extend from the subiculum and travel to the entorhinal cortex where other
output fibers travel in pathways throughout the cerebrum, completing the pathway and flow
of information [82].
Olfactory information is processed into long-term memory though the hippocampus. Sensory
olfactory and synaptic information that is processed in the main olfactory bulb is sent to the
piriform cortex and close to the orbital prefrontal cortex (PFC). The main olfactory bulb and
these cortices project into the entorhinal cortex and the perirhinal area which relays the
information through the perforant pathway to the hippocampus. Projections from the
parahippocampal region extend to the piriform cortex, enabling a reciprocal and intercon‐
nected neural linkage [83].
Neural plasticity changes neuronal connectivity in the hippocampus. Through long-term
potentiation and long-term depression (LTP), synaptic connections in the hippocampus are
strengthened or weakened, respectively. Intracellular calcium release in postsynaptic neuron
determines the level of neural plasticity. Receptors for CB1 are found throughout the
hippocampus and are central to calcium-induced inhibition. The presence of the CB1R
indicates that the hippocampus can be subject to depolarization-induced suppression of
inhibition (DSI) which conversely affects the release of GABA from GABAergic neurons [10].
When endocannabinoids, 2-AG, and AEA are released by postsynaptic hippocampal neurons,
GABAergic interneurons are inhibited, thus relieving principal neurons such as hippocampal
pyramidal cells from inhibition [26]. This affects the information flow along the perforant
pathway. The presence of more GABA increases the level of LTP and less GABA increases the
amounts of long-term potentiation [26, 81] which affects memory production and learning.
Unlike classical neurotransmitters, endocannabinoids can function as retrograde synaptic
messengers. After release from postsynaptic neurons, they travel backward across synapses,
activate CB1R on presynaptic axons, and suppress neurotransmitter release in order to
modulate their inputs. The transient suppression of GABA-mediated transmission that follows
depolarization of hippocampal pyramidal neurons is mediated by retrograde signaling
through release of endogenous cannabinoids. Mechanistically, activation of CB1R inhibits
presynaptic calcium channels through direct G-protein inhibition [27]. These synapses are
unusual among brain synapses in that they use N- but not P/Q-type calcium channels for
neurotransmitter release. A combination of patch-clamp electrophysiology in cultured
hippocampal slices, calcium measurements, and flash photolysis of caged compounds, such
as caged AEA, has allowed determining the temporal kinetics of the hippocampal
endocannabinoid signaling cascade [15]. AEA and, by extension, other lipid signaling
molecules do not simply serve long-term neuromodulatory functions but they are sufficiently
fast to exert moment-to-moment control of synaptic transmission indicating that
endocannabinoids are highly selective, rapid modulators of hippocampal inhibition.
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7. Cannabinoid receptors as regulators of emotional memory
The amygdala is an almond-shaped nuclear structure located within the temporal lobe. It can
be subdivided into three major nuclei: the basolateral nuclear complex, the central nucleus,
and the medial nucleus. At the neuronal level, the emotional memory and emotional processes
involve a brain network with limbic circuits including the amygdala, the medial PFC, and the
anterior insula [84–87]. The amygdala is typically activated in response to emotional events,
for example, dangerous situations by triggering and processing anger and fear [88]. Fear-
conditioning experiments have delineated an amygdala-hippocampal-cortico-striatal circuit
as a key brain circuit responsible for processing and storing fear-related memories and for
coordinating fear-related behaviors [89, 90].
The basolateral amygdala is a critical component in the learning of conditioned fear responses
[91], emotional processing, and encoding of associative memories with an affective component
[92–95]. Animals with lesions to the basolateral amygdala complex produce serious deficits in
learning new fear responses in a number of different conditioning tasks [96–99].
High levels of CB1R expression in the amygdala are observed in adult, fetal, and neonatal
brains [58, 100–103] including GABAergic axonal terminals of the amygdala [104]. Endocan‐
nabinoids are known to retrogradely activate presynaptic CB1 receptors and modulate the
release of several neurotransmitters (glutamate and GABA) [7, 15, 105]. Endocannabinoids
regulate anxiety- and depressive-like behaviors mostly via stimulation of CB1R in emotion-
related circuits of the PFC, amygdala, hippocampus, and cerebellum [7, 9, 87, 106–108].
Experiments with CB1R knockout mice revealed anxiogenic- and depressive-like phenotypes
[109–111]. CB1 receptors play an important role in social interaction and aggressive behavior
[107]. CB1 receptors in the amygdala and other brain areas such as the PFC have been shown
to be critically involved in emotional learning and memory [112–117] and in fear learning,
consolidation, retrieval, and extinction [118]. Using the fear-potentiated startle (FPS) para‐
digm, fear memory consolidation and retrieval, as well as extinction, were observed to be
regulated differentially by amygdaloid and cortical CB1Rs [118]. Amygdala CB1Rs are
involved in the development and maintenance of nicotine abstinence-related social anxiety-
like behavior following a behaviorally sensitizing nicotine regimen. This suggests that changes
in CB1R expression may contribute to perpetuation of nicotine relapse in vulnerable high
responders, that is, in a rat model of novelty-seeking phenotype where animals respond with
high locomotor reactivity to novelty [119].
It was found that CB1R expression is sensitive to stressful experiences, as animals submitted
to a fear-conditioning paradigm presented CB1R upregulation in the PFC [90, 120]. Exposure
to shock or stressful environments leads to an increase in endocannabinoids [121] and
increased endocannabinoid release [9, 122] in the amygdala. Therefore, CB1R was considered
as being a significant modulator for amygdala responses in social emotional negative situations
[87].
The neuronal endocannabinoid system modulates synaptic transmission and plasticity via its
two principal signaling lipids, AEA and 2-AG. It is commonly thought that both endocanna‐
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binoid-mediated short- and long-term plasticities are mediated through synaptic retrograde
mechanisms with presynaptic CB1Rs [11, 68, 122–124]. However, polymodal activation of the
endocannabinoid system has recently been found in the extended amygdala [125], that is, AEA
and 2-AG are responsible for different forms of synaptic plasticity. Release of 2-AG triggered
CB1R-mediated, retrograde, short-lasting inhibition of transmitter release, whereas mGluR5-
dependent release of AEA activated postsynaptic TRPV1 receptors (transient receptor
potential V1) and resulted in LTP [125]. The production of both endocannabinoids and
different signaling pathways allows a single BNST (bed nucleus of the stria terminalis) neuron
to take on two different forms of synaptic plasticity via the release of either 2-AG or AEA such
that the endocannabinoid system acts as a polymodal signal integrator to diversify synaptic
plasticity at the level of individual neurons [125].
It has been reported that in the amygdala FAAH, the enzyme that degrades AEA aggravates
stress, whereas AEA protects and helps with recovery from stress [126]. Exposure to stress
rapidly mobilizes FAAH to deplete the available pool of AEA and increases neuronal excita‐
bility in the basolateral amygdala, an anxiety-mediating region [126]. When FAAH is geneti‐
cally deleted and pharmacologically inhibited, stress-induced reductions in AEA are
prevented. Along the same line, long-term fear extinction is facilitated when FAAH is inhibited
suggesting that the restoration of AEA levels in the basolateral amygdala by blocking FAAH
with drugs might be clinically relevant to treat traumatic stress disorders.
The endocannabinoid system has become a major focus in the search for pharmacological
interventions for fear extinction (for review see [91, 127, 128]). CB1R agonists and antagonists
generate diverse cognitive effects and change extinction learning. CB1R is implicated in the
sensory processing and learning. CB1R is expressed at high levels in the medial PFC, hippo‐
campus, and basolateral amygdala. CB1R affects synaptic transmission and plasticity such as
LTP in these brain areas.
Impairment of CB1R signaling affects the neuronal excitatory/inhibitory balance with effects
on emotional function and anxiety- or depressive-like behaviors [129–132]. Drug use often
starts during adolescence. During this time, the structure and function of the developing brain
are particularly receptive to external stimuli such as cannabis. Adolescence is critical in the
emergence of mental illness prior to its manifestation in adults but how does adolescent
cannabis use affect brain development and function? Indeed, synaptic CB1R expression in
adult mouse brain amygdala regions is downregulated by adolescent THC exposure, that is,
it affects brain structure and function [133]. A recent study shows broad CB1R/b-arrestin2 co-
expression in the medial PFC, amygdala, and hippocampus. This is paralleled by impairment
of extracellular signal-regulated kinase signaling and elevation of vesicular glutamate
transporter (VGluT1) at CB1R-expressing excitatory terminals in the medial PFC or vesicular
GABA transporter (VGAT) at CB1R-expressing inhibitory terminals in the amygdala and
hippocampus [132]. These alterations play a key role in the etiology of anxiety-like behaviors
when occurring in the PFC, amygdala, and hippocampal circuits [129, 131].
Emotional dysfunction has been considered a hallmark of schizophrenia dating back to early
days of research. Emotional disturbances in brain circuits, especially the amygdala, play a key
part in symptoms of schizophrenia [134]. Adolescent cannabis use is an environmental risk to
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exacerbate cognitive and emotional behavioral abnormalities in individuals with genetic
vulnerabilities [133].
Deficiency of CB1R signaling is associated with anxiety and persistence of negative memories
[135]. Endocannabinoid-CB1R signaling is reduced with pharmacologic antagonists or genetic
deletion [136–138]. Blockade of endocannabinoid-CB1R signaling with CB1R antagonists
results in increased anxiety-like behaviors [135, 139] and also results in delayed and ineffective
extinction of fearful memories in an animal model [9]. Administration of CB1R antagonist to
healthy humans increases anxiety [140]. Indeed, anxiety is a main adverse effect in humans
treated with a CB1R antagonist for metabolic disorder and obesity [141]. Patients, particularly
those with prior depressive symptoms, exhibit increased depressive symptoms, including
suicidality after treatment with CB1R antagonists [142].
Endocannabinoids are strongly linked to stress, fear, and anxiety, which has led to a growing
interest in developing novel medication for anxiety and other psychological disorders
targeting the endocannabinoid system [126]. Robusting endocannabinoid-CB1R signaling is
vital for appropriate stress responses and for the maintenance of emotional homeostasis,
particularly in the face of chronic stress. Understanding the underlying mechanisms of
endocannabinoids in controlling stress, fear, and anxiety has grown considerably in recent
years, with some targets already having been advanced to preliminary clinical trials in patients
[126].
8. Endocannabinoids as neuroprotective agents
Studies highlighting the effects of endocannabinoids point to their neuroprotective role in the
brain. Endocannabinoid-like compounds such as arachidonoyl serine (AraS), which has a
similar structure to the endocannabinoid 2-AG, have been found to reduce lesion size follow‐
ing the induction of traumatic brain injury in mice [143]. Brain diseases have been shown to
cause alterations to endocannabinoid synthesis. In Alzheimer’s disease, FAAH, the enzyme
which terminates endocannabinoid signaling, is epigenetically regulated. Patients with late-
onset Alzheimer’s disease, LOAD patients, display an increase in FAAH, whereas other
components of the endocannabinoid system remain unchanged [144]. Another example of
alteration of FAAH resulting in an increase in endocannabinoid system activation has been
shown through application of an FAAH inhibitor. Use of the FAAH inhibitor, PF3845, in a
mouse model helped to relieve traumatic brain injury-induced impairments including
impairments of fine motor movement, hippocampus-dependent working memory, and
anxiety-like behaviors. An FAAH inhibitor can result in the promotion of neuronal survival,
attenuation of inflammation, and improvement of functional recovery following traumatic
brain injury [145]. Traumatic brain injury is the leading cause of death in young people in the
USA. Therefore, studies on FAAH potentially have great benefit to society in terms of treating
traumatic brain injury.
The endocannabinoid system has also been shown to be neuroprotective during neurological
diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis, and drug addiction. A role
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of endocannabinoids has been shown in Alzheimer’s disease when WIN 55,212-2, a CB1R
agonist, was tested on the effect of the toxic peptide Aβ1–42 in cultured astrocytes. Peptide
Aβ1–42 accumulates during Alzheimer’s disease causing cellular damage. Treatment with
WIN 55,212-2 resulted in an increase in cellular viability of astrocytes and a decrease in
inflammation [146]. An area of current investigation is the role of endocannabinoids as
neuroprotectants in motor degeneration diseases. In one study, endocannabinoids played a
neuroprotective role in amyotrophic lateral sclerosis [147]. In addition to endogenous canna‐
binoids assisting in ameliorating the effects of disease such as traumatic brain injury and
neuropathic pain, research has also shown that endocannabinoids help to reduce the effects
of drugs of abuse on the brain, in particular amphetamine abuse. THC, an exogenous form of
cannabinoid, has been shown to reduce the neurotoxicity of methamphetamine by reducing
the methamphetamine-induced overexpression of neuronal nitric oxide synthase in the
caudate putamen [148].
Endocannabinoids have been shown to play a neuroprotective role in the limbic system. CB1R
in both the hippocampus and amygdala is sufficient for synaptic and behavioral functions. In
a study using conditional CB1R knockout mice, genetic restoration of wild-type CB1R function,
specifically in dorsal telencephalic glutamatergic neurons, fully restored hippocampus-
dependent neuroprotection from chemically induced epileptic-like seizures [149]. Dopamine
receptor (D3 receptor) null mice have been shown to exhibit changes in levels of endocanna‐
binoid and TRPV1 (transient receptor potential cation channel subfamily V member 1, also
known as the capsaicin receptor and the vanilloid receptor 1), but not in CB1R in the hippo‐
campus, nucleus accumbens, amygdala, and striatum. This change is related to less anxious-
like behavior when mice underwent the elevated maze plus test. Hence, the endocannabinoid
and endovanilloid systems may interact with dopamine receptors in order to produce normal
responses to excitotoxic or anxiogenic stimuli [150]. Following exposure to foot shocks and
situational reminders which mimic post-traumatic brain disorder in mice, treating mice with
WIN 55,212-2, leads to normalization of CB1R upregulation in the PFC and CA1 of the
hippocampus. Consequently, cannabinoids aid in emotional processing by preventing the
distraction of foot shock followed by situation reminders [90].
The endocannabinoid AEA has been shown to protect HT22 cells exposed to hydrogen
peroxide. This occurs via inhibition of NADPH oxidase 2 (Nox2). Activation of neuronal Nox2
enhances oxidative damage of the brain, and inhibition of Nox2 can attenuate cerebral
oxidative stress [151]. Using a mouse model of oxidative stress by exposing hippocampal HT22
cells (mouse hippocampal neuron cell line HT22) to hydrogen peroxide, researchers tested
whether AEA can attenuate the effects of oxidative stress on the brain. Cells exposed to
hydrogen peroxide and treated with AEA were shown to experience fewer symptoms of
oxidative stress such as morphological changes, decreased lactate dehydrogenase (LDH)
release, reduced metabolic activity, increased levels of intracellular reactive oxygen species
(ROS) and oxidized glutathione (GSSG), reduced levels of superoxide dismutase (SOD) and
neuronal glutathione (GSH), and increased expression of neuronal Nox2, a contributor to
oxidative damage to the brain. AEA was shown to prevent the oxidative stress effects unless
the CB1R antagonist AM251 is simultaneously administered [151].
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Endocannabinoid action is needed for normal activation of focal adhesion kinase (FAK) and
extracellular signal-regulated kinase (ERK ½, ERK1/ERK2 subtypes) induced synaptic
integrity in the hippocampus. This has been determined by treating hippocampal cells with
endocannabinoid antagonist AM281, resulting in FAK and ERK ½ activation being blocked.
The blocking of FAK and ERK ½ results in a decrease in synaptic markers. These results
support the notion that the endocannabinoid system is the key for the integrity and mainte‐
nance of synapses in the hippocampus [152]. Endocannabinoid signaling can be modulated
not only through direct activation of CB1 receptors but also through inhibition of endocanna‐
binoid transport and FAAH, two mechanisms of endocannabinoid inactivation. Dual modu‐
lation of endocannabinoid transport and the enzyme FAAH results in protection against
excitotoxicity. When hippocampal slices are exposed to excitotoxic insult and then treated with
endocannabinoid transport blocker AM404 and FAAH blocker AM374, neuroprotection
occurs against cytoskeleton damage and a decrease of synaptic decline. Likewise, the blockers
protect against behavioral impairment and memory impairment characteristic of excitotoxic
insult [153]. In the hippocampus THC has been shown to protect neurons from excitotoxicity.
Both WIN 55122, a full CB1R agonist, and THC, a partial CB1R agonist, elicit a neuroprotective
effect on rat hippocampal cells when the cells are excitotoxically stimulated to mimic disease-
generated excitotoxic neuronal death [154]. CB1R also plays a role in neural progenitor
proliferation and neurogenesis induced by excitotoxicity. During excitotoxicity the brain will
attempt to repair damage by stimulating neural progenitor cells. When CB1R is inhibited in
the hippocampus, both basic fibroblast growth factor (bFGF) and epidermal growth factor
(EGF), key factors in neural progenitor stimulation, are blocked [155]. Excitotoxicity results in
an increase in CB1R-positive and bFGF-positive cells, which proceeds neural progenitor cell
proliferation. These results point to the importance of the endocannabinoid system in cellular
regeneration from excitotoxic cellular damage in the hippocampus [155]. The endocannabinoid
N-arachidonoyldopamine (NADA) has been shown to exert a neuroprotective effect in
response to excitotoxic neuronal damage [156]. The neuronal damage occurs via CB1R.
Excitotoxic lesioning of hippocampal slices by applying N-methyl-D-aspartate (NMDA), and
subsequent treatment with NADA, determines whether endocannabinoids can be neuropro‐
tective. NADA treatment protects dentate gyrus cells in organotypic hippocampal slice
cultures. At the same time, the number of phagocytic microglia, which are attracted to sites of
brain injury, decreases slightly [156].
Additionally, endocannabinoids have been shown to be neuroprotective in other disorders
and anatomical systems such as obesity, endocannabinoid deficiency syndrome, and anti-
inflammation. The endocannabinoid system has a direct relation with obesity because
rimonabant (SR141716, trade names Acomplia, Zimulti), an anorectic anti-obesity drug, is an
inverse agonist for CB1R. Rimonabant is a selective CB1 receptor blocker that was originally
approved for use but has been withdrawn from the market because of potentially negative
side effects. Since rimonabant has been shown to be an anti-obesity drug by inactivating the
endocannabinoid system, it can be argued that the endocannabinoid system when activated
can assist with weight gain, an issue faced by people experiencing weight-compromising
diseases including cancer and people facing food absorption diseases including Crohn’s
disease [157]. The endocannabinoid system can potentially be used in clinical interventions. A
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growing area of research documents the “endocannabinoid deficiency syndrome” which is
linked to migraine, fibromyalgia, irritable bowel syndrome, and psychological disorders [158].
Activation of nuclear receptor protein peroxisome proliferator-activated receptor-gamma has
been shown to play a key role in the neuroprotective anti-inflammatory role of 2-AG in the
brain [159].
Endocannabinoids and their receptors are expressed through the central nervous system and
immune system suggesting a critical functional role for endocannabinoids in the operation of
these systems. Activation of the endocannabinoid system is directly related to bodily recov‐
ery from a disease state such that endocannabinoids play a neuroprotective role in the nervous
and immune system. This neuroprotective effect can be seen specifically in response to
neurological disorders and injury such as Alzheimer’s disease and traumatic brain injury.
Likewise, endocannabinoids show neuroprotective effects following spinal cord injury. These
data suggest that the endocannabinoid system as a neuroprotective agent has the potential for
new therapeutic interventions during diseases of the nervous system and immune system.
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